Wuding Reports June 2026 Revenue of NT$174 Million, Up 20.1% Year-on-Year

Company Code: 1733 Company Name: Wuding Industry: Biotechnology and Healthcare Reporting Period: June 2026 Monthly Revenue: NT$173,952 thousand (NT$174 million) Year-on-Year Change: +20.1%

Keywords: Monthly Revenue, Biotechnology and Healthcare Industry

Wuding reported revenue of NT$173,952 thousand (approximately NT$174 million) for June 2026, marking a 20.1% increase compared to the same month last year. This growth reflects strong market demand and improved market recognition of the company's products and services within the biotech and healthcare sector.

The company focuses on the research and development of medical technologies, particularly diagnostic equipment and biopharmaceuticals tailored to an aging society. The revenue increase is likely driven by successful product launches and expanded orders from existing clients.

The broader biotech and healthcare industry continues to benefit from government support and increased private investment, accelerating innovation. Wuding's performance indicates strengthened competitiveness amid these trends, raising expectations for continued growth.

Looking ahead, potential international expansion and strategic partnerships are drawing attention from investors and industry stakeholders.